【投资要点】近年来,中国创新药在全球医药市场中的影响力显著提升,中国正在进行的临床试验数量持续上升。根据药智网统计数据,截至6 月4 日,2025 年我国国产创新药发生BD 交易近80 项,其中License out 项目近60 项,License in 项目近20 项目。从已公布金额数据的项目来看,License out 项目涉及金额512 亿美元。我国PD-(L)1/VEGF-(A)双抗迎来...
Source Link【投资要点】近年来,中国创新药在全球医药市场中的影响力显著提升,中国正在进行的临床试验数量持续上升。根据药智网统计数据,截至6 月4 日,2025 年我国国产创新药发生BD 交易近80 项,其中License out 项目近60 项,License in 项目近20 项目。从已公布金额数据的项目来看,License out 项目涉及金额512 亿美元。我国PD-(L)1/VEGF-(A)双抗迎来...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.